<DOC>
	<DOC>NCT01588028</DOC>
	<brief_summary>CH5424802 is a newly invented, selective oral ALK inhibitor. In the Phase I portion, the goal is to determine the following: dose limiting toxicity, the maximum tolerated dose, pharmacokinetic (PK) parameters, and the recommended dose.</brief_summary>
	<brief_title>A Clinical Study Testing The Safety and Efficacy of CH5424802/RO5424802 in Patients With ALK Positive Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<criteria>ECOG performance status =&lt; 2 Confirmed of ALKpositive NSCLC by FDA approved kit NSCLC that has failed crizotinib treatment for Phase I Measurable disease defined by RECIST 1.1 Adequate hematologic, hepatic, renal function Prior therapy with an ALK inhibitor other than crizotinib Brain metastases, which are symptomatic and/or requiring treatment History of serious cardiac dysfunction Clinically significant gastrointestinal abnormality that would affect the absorption of drug Pregnant or a lactating woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>